Last reviewed · How we verify
Isoniazid treatment
At a glance
| Generic name | Isoniazid treatment |
|---|---|
| Sponsor | Asan Medical Center |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety and Tolerability of Metformin in People With Tuberculosis (TB) and Human Immunodeficiency Virus (HIV) (PHASE2)
- An Adaptive Multi-arm Trial to Improve Clinical Outcomes Among Children Recovering From Complicated SAM (PHASE3)
- Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis (PHASE2)
- Isoniazid-Related Hepatotoxicity in Clinical Practice: Incidence and Predictors
- AIPH-TB: AI-Optimised Pyrazinamide-Hydroxychloroquine vs Standard RIPE for Drug-Sensitive Pulmonary Tuberculosis - A Phase II RCT (PHASE2)
- Digitally Facilitated, Integrated Community and Facility-Based Interventions: The HEART-TB Trial Protocol (NA)
- Ultra-Short Course Bedaquiline, Clofazimine, Pyrazinamide and Delamanid Versus Standard Therapy for Drug-Susceptible TB (PHASE2)
- Asymptomatic TB With Innovative Modified Short-course Regimens (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Isoniazid treatment CI brief — competitive landscape report
- Isoniazid treatment updates RSS · CI watch RSS
- Asan Medical Center portfolio CI